Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The transcript is about BellRing Brands, a consumer packaged goods company selling protein shakes and powders. The "engagements" here would be orders, distribution deals, capacity, etc. But the question is about the size of individual deals/orders/projects/customers/sites/programs. The company is growing, but is it that each new instance is bigger? For example, are they signing larger contracts? They talk about capacity expansion, new co-manufacturers, distribution gains. But the question is about the size of what they land individually. They mention "distribution gains" and "TDPs" (total distribution points) increasing. But that's more about breadth, not necessarily size per engagement. They also talk about new flavors, promotions. There's no mention of average order size increasing, or customers starting at larger scale, or follow-on commitments at multiples. They talk about production capacity growing, but that's supply, not demand size per engagement. They mention "we gained meaningful new shelf space" but that's not necessarily larger per engagement. The question is about the unit size of repeatable business escalating. I don't see any explicit statement that each new deal is bigger than the last. They talk about growth in volume, but that could be from more distribution points, not larger per point. They also mention "our second greenfield facility" starting up, but that's capacity. No mention of larger orders. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.